医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

3D Printing 2017, Additive Manufacturing Technology Exhibition, Brings You the Latest Information on the Cutting Edge 3D Printing Technologies, Design, Manufacturing and Materials Making

2017年01月31日 AM11:52
このエントリーをはてなブックマークに追加


 

TOKYO

JTB Communication Design, Inc. will be holding “3D Printing 2017” – the Cutting Edge 3D Printing Technologies exhibitions, now in its 3rd year – on February 15, 2017, at the Tokyo Big Sight convention center in Japan. 78 organizations (including over 37 first-time exhibitors) from 6 countries and regions are set to exhibit at the event in 102 booths (about 1,000sqm), demonstrating revolutionary and cutting edge core technologies. The concurrently held exhibitions, the total number of visitors to the event are expected to exceed 50,000.

 

3D Printing 2017 Additive Manufacturing Technology Exhibition

Date:   February 15-17, 2017, 10:00-17:00
Venue: Tokyo Big Sight (East Halls 6)
Organizer: JTB Communication Design
Nanotechnology Business Creation Initiative (NBCI)

View source version on businesswire.com: http://www.businesswire.com/news/home/20170130006262/en/

CONTACT

Secretariat of 3D Printing (c/o JTB Communication Design)
Ms. Mika
Seshima, +81-3-5657-0760
3dpritning@jtbcom.co.jp
http://www.3dprintingexpo.jp/index_en.html

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil
  • SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • 首例神经母细胞瘤患者成功接受采用自然杀伤T细胞(CAR-NKT)的创新型CAR疗法